673 results on '"Andersen, Mads Hald"'
Search Results
2. Novel immune modulatory vaccines targeting TGFβ
3. Novel immunotherapeutic combinations moving forward: the modulation of the immunosuppressive microenvironment
4. State-Of-The-Art Advancements on Cancer Vaccines and Biomarkers
5. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
6. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.
7. Characterization of TGFβ-specific CD4+T cells through the modulation of TGFβ expression in malignant myeloid cells
8. Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner
9. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer
10. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
11. Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
12. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms
13. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow
14. Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
15. Survivin
16. Cancer immune therapy for lymphoid malignancies: recent advances
17. The T-win® technology: immune-modulating vaccines
18. Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
19. Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
20. Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
21. Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
22. Table S2 from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
23. Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
24. Supplementary Data from MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells
25. Supplementary Data from Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade
26. Data from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
27. Supplementary Figure S1-S5 from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
28. Supplementary figure from Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
29. Supplementary Figures 1-6 and Supplementary Table 1 from Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
30. Supplementary Methods from Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling
31. Supplementary Methods from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
32. Supplementary Figure 1 from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
33. Supplemental Figures S1-S10 from Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
34. Data from Spontaneous Cytotoxic T-Cell Reactivity against Indoleamine 2,3-Dioxygenase-2
35. Supplementary Figure 2 from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
36. Supplementary Figure Legend from HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
37. First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer
38. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
39. Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome
40. Anti-cancer immunotherapy: breakthroughs and future strategies
41. Autocrine CCL19 blocks dendritic cell migration toward weak gradients of CCL21
42. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial
43. Immune modulatory vaccines: time to move into infectious diseases
44. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer
45. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
46. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.
47. Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV
48. Therapeutic Potential of an Immune-Modulatory Vaccination Targeting Myeloid-Derived Suppressor Cells in Myelodysplastic Syndrome
49. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
50. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.